MIGAL Galilee Research Institute

 

Ari Meerson

We study the molecular basis of chronic diseases, focusing on the function of microRNAs. MicroRNAs may act as a functional link between different chronic diseases, and hold promise as potential biomarkers and therapeutic targets. Specifically, we are interested in:

  1. MicroRNAs as a mechanistic link between metabolic disease and cancer

  2. Discovery of microRNA-based biomarkers in body fluids

Expertise

  • Gene expression analysis

  • microRNA target validation

  • Quantification and manipulation of microRNA levels in cells, tissues and biofluids

  • RNA-seq

  • RT-qPCR

  • Immunoblots

  • Immunostaining

Interested in collaborating on

Although I'm open to many types of collaboration, as a molecular biologist, I'm specifically looking for clinicians who would have access to samples, resources and knowledge complementary to my own.

Selected publications on lncRNA

Elevated Levels of miR-122 in Serum May Contribute to Improved Endothelial Function and Lower Oncologic Risk Following Bariatric Surgery. Blum A, Yehuda H, Geron N, Meerson A. Isr Med Assoc J. 2017, 19(10):620-624.

Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α. Meerson A, Traurig M, Ossowski V, Fleming JM, Mullins M, Baier LJ. Diabetologia. 2013, 56(9):1971-9.

MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H. Immunity. 2009, 31(6):965-73.

MicroRNA modulation of megakaryoblast fate involves cholinergic signaling. Guimaraes-Sternberg C, Meerson A, Shaked I, Soreq H. Leuk Res. 2006, 30(5):583-95.

Website
arim@migal.org.il

PO Box 831
Kiryat Shmona
1101602 Israel